(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Amgen today is the biggest biotechnology company ... Members of staff “drove beat up cars and rode their bikes to work” and took part in a company culture that would work late, but also ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Joy Spence, a 21-year-old social work student from Flatrock, N.L., is among several women who told CBC News their pain and ...

Amgen is focusing deeply on its efforts to treat obesity, the CFO said Wednesday. But Amgen stock dipped a fraction in late trades.

Amgen’s next-generation cholesterol drug has ... We look forward to our outcomes study, FOURIER, and will continue to work with payers to improve access for patients who need additional LDL ...

Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.

Biotechnology firm Amgen has been awarded menopause-friendly employer accreditation as part of its aim to ensure all of its ...

Amgen’s third-quarter product sales grew 24 ... Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their ...